- Niflumic acid Impurity
-
- $0.00 / 20mg
-
2025-04-18
- CAS:4394-00-7
- Min. Order: 20mg
- Purity: 98
- Supply Ability: 10000000
- Niflumic acid
-
- $44.00 / 50mg
-
2024-11-19
- CAS:4394-00-7
- Min. Order:
- Purity: 99.79%
- Supply Ability: 10g
- Niflumic acid
-
- $44.00 / 50mg
-
2024-11-19
- CAS:4394-00-7
- Min. Order:
- Purity: 99.79%
- Supply Ability: 10g
|
| | Niflumic acid Basic information |
| | Niflumic acid Chemical Properties |
| Melting point | 203-204 °C | | Boiling point | 378.0±42.0 °C(Predicted) | | density | 1.3935 (estimate) | | storage temp. | 2-8°C | | solubility | Soluble in ethanol (~50 mg/ml), acetone (50 mg/ml, Clear to Slightly Hazy, Yellow), methanol (~50 mg/ml), DMSO (56 mg/ml at 25°C), and acetonitrile (~50 mg/ml). | | pka | pKa 2.26 ± 0.08;4.44± 0.03(H2O,t =25±0.1,I=0.01(NaCl))(Approximate) | | form | Solid | | color | Light orange to Yellow to Green | | biological source | synthetic (organic) | | Water Solubility | 19mg/L(room temperature) | | Sensitive | Light Sensitive | | Merck | 14,6531 | | Stability: | Stable, but may discolour in light. Incompatible with strong oxidizing agents. Hygroscopic. | | InChIKey | JZFPYUNJRRFVQU-UHFFFAOYSA-N | | NIST Chemistry Reference | Niflumic acid(4394-00-7) | | EPA Substance Registry System | 3-Pyridinecarboxylic acid, 2-[[3-(trifluoromethyl)phenyl]amino]- (4394-00-7) |
| Hazard Codes | Xn | | Risk Statements | 20/21/22-36/37/38 | | Safety Statements | 26-36-36/37/39 | | RIDADR | UN 2811 6.1/PG 3 | | WGK Germany | 3 | | RTECS | QT2999100 | | HazardClass | 6.1 | | PackingGroup | Ⅲ | | HS Code | 29333999 | | Toxicity | LD50 in rats (mg/kg): 370 orally; 155 i.p. (Sorenson) |
| | Niflumic acid Usage And Synthesis |
| Chemical Properties | Crystalline Solid | | Originator | Nifluril,U.P.S.A.,France,1968 | | Uses | analgesic, antiinflammatory | | Uses | Anti-inflammatory. Selective cyclooxygenase-2 (COX-2) inhibitor | | Uses | Niflumic acid is used for the exact same indications as the drugs described above. Synonyms for this
drug are actol, flunir, nifluril, and others. | | Definition | ChEBI: Niflumic acid is an aromatic carboxylic acid and a member of pyridines. | | Manufacturing Process | Niflumic acid is prepared as follows: Nicotinic acid, m-trifluoromethylaniline,
and potassium iodide are intimately mixed and heated on an oil bath at
140°C. The mixture melts to give a dark red liquid. The temperature of the oil
bath is allowed to fall to 100°C and is maintained at this temperature for an
hour and a half. The mixture puffs up and forms a yellow crystalline mass.
After cooling to ordinary temperature, this mass is ground up in a mortar and
extracted several times with small volumes of ether to remove excess mtrifluoromethylaniline. The residue is then washed twice with 10 ml of distilled
water to remove m-trifluoromethylaniline hydrochloride and potassium iodide,
and finally twice with 10 ml of 95% alcohol to remove colored resinous
contaminants. After drying at 100°C, 2-(m-trifluoromethylanilino)nicotinic acid
is obtained as pale yellow needles (from 70% ethanol) melting at 204°C
(Kofler block). | | Therapeutic Function | Antiinflammatory | | Trade name | Actol (Mayrhofer, Austria;
Upsamedica, Spain), Donalgin (Gedeon Richter,
Hungary), Livornex (Genepharm, Greece), Ni-
flam (Upsamedica, Italy), Nifluril (UPSA,
France; Upsamedica, Belgium, Switzerland,
Portugal). | | Biochem/physiol Actions | Niflumic acid (NFA), a γ-aminobutyric acid type A receptor (GABAARs) antagonist is a non-steroidal anti-inflammatory drug (NSAID) and it belongs to the fenamate class. It is also a blocker of chloride ion channel and a calcium-activated chloride channel (CaCC) inhibitor. NFA possesses anti-inflammatory property and is useful in treating rheumatic disorders. It is also an inhibitor of N-methyl-D-aspartate receptor and glycine receptor. NFA also inhibits enzymes associated with the prostaglandins synthesis. | | Side effects | Niflumic acid has been used effectively to
treat rheumatoid arthritis, psoriatic arthritis, and
hypertrophic osteoarthritis of the hip and knee.
Gastric complications are the chief adverse effects of this drug. | | Synthesis | Niflumic acid, 2-3-(trifluoromethyl)anilino nicotinic acid (3.2.21), is synthesized either by the reaction of 2-chloronicotinic acid with 3-trifluoromethylaniline
[84¨C86], or 2-aminonicotinic acid with 1-bromo-3-trifluoromethylbenzene [87]. 
|
| | Niflumic acid Preparation Products And Raw materials |
|